Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2017

At a glance

  • Drugs STX 100 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Sponsors Biogen
  • Most Recent Events

    • 18 May 2017 Status changed from active, no longer recruiting to completed.
    • 26 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 11 Apr 2017 Planned number of patients changed from 40 to 41.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top